Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Impact assessment: European Commission explains basis for ATPs

This article was originally published in Clinica

Executive Summary

There was absolutely no doubt in the minds of the European Commission experts, when it came to arguing the case of whether a new regulatory framework was needed for human tissue engineered products (hTEPs), that this was indeed essential for the sake of clarity for business, in order to remove obstacles to free trade and to ensure patients benefit from the innovative therapies they offer.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel